Breaking News

MSK radiologist and Fox contributor is the new surgeon general nominee

May 1, 2026
avatar-angus-chen
Cancer Reporter

The immediate news is that President Trump has nominated Memorial Sloan Kettering’s Nicole Saphier to be the next U.S. Surgeon General. Saphier is a radiologist and is the director of breast imaging at MSK Monmouth, which is a location in New Jersey. Saphier seems to be most known for her commentary in Fox News. In covering the nomination, the STAT staff took a little time yesterday morning to look at some of Saphier’s opinions.

Most of what I saw on cancer hews pretty close to established guidelines (like mammography after age 40). What stood out was Saphier’s approach to the rise of early-onset cancer. In some of her opinion writing, Saphier appears to endorse this idea of having children at an earlier age to reduce breast cancer risk. That’s something that I would anticipate as being controversial. Though, she adds in this op-ed that what society needs are policies that provide access to things like affordable, healthy foods and safe housing. That might imply a belief in a social safety net to make it possible for people to have children earlier.

Having read only a little bit about Saphier, this raises some questions about what kind of Surgeon General she might be and what kinds of lifestyle, health, or medical advice and guidelines she would provide the American public. To me, it’ll be interesting to see if as Surgeon General she would depart from established guidelines to advice things like not delaying having children and try to influence culture or policy in that way, if she tackles cancer at all.

Can’t believe it’s already (and somehow only) May.


Nicole Saphier, now the nominee for surgeon general, attends FOX Nation's Patriot Awards in 2024.
Theo Wargo/Getty Images

STAT+ | In her own words: Surgeon general nominee Nicole Saphier expresses enthusiasm and caution for MAHA

Examining the past statements and writings of Trump's third surgeon general nominee, Dr. Nicole Saphier, on vaccines, autism, peptides, diet and more.

By Elizabeth Cooney, Helen Branswell, and Katie Palmer


STAT+ | What does Akeso’s primo plenary spot say about its survival data?

In the runup to the American Society of Clinical Oncology, good bit of the Wall Street chatter is centered on the Akeso-Summit Therapeutics.

By Adam Feuerstein


Securing NIH awards is getting more competitive — and confusing

NIH payline crash: Why the drop in grant success rates, disappearing NOFOs, and political shifts are crippling academic research careers.

By Anil Oza



Matt Houston/AP

Remembering J. Craig Venter: a relentless scientist who changed biotech — and was all too easily misunderstood

Venter, who died Wednesday at age 79, is remembered by STAT columnist Matthew Herper as a brilliant scientist, innovator, and 'easy man to misunderstand.'

By Matthew Herper


More around STAT

In other news

  • They're in remission, but their medical bills aren't: Cancer survivors navigate soaring costs, KFF Health News
  • AstraZeneca shares dip after US regulatory panel rejects breast cancer drug, Reuters
  • To catch colorectal cancer early, advocates push to make "poop talk" OK, NPR

Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Cancer Briefing? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2026, All Rights Reserved.

No comments